One-in-a-trillion – understanding single-cell sequencing to understand preeclampsia
Current Status and Prospects of the Single-Cell Sequencing Technologies for Revealing the Pathogenesis of Pregnancy-Associated Disorders
The adult human body is made up of about 100 trillion cells. In this article, researchers review the current published literature for single-cell sequencing and pregnancy-associated disorders. Single-cell sequencing is the technique of measuring gene expression within an individual cell. Single-cell sequencing can lead to new discoveries by 1) showing how gene expression profiles look in healthy cells, 2) helping us understand how the biology inside different cell types compares, and 3) also, by identifying cells that don’t have expected gene expression profiles, giving clues to how diseases develop. Single-cell sequencing technologies were only developed 14 years ago but have already allowed for many discoveries in pregnancy-associated disorders like diabetes and preeclampsia. Single-cell sequencing in preeclampsia research has focused largely on studying the gene expression of trophoblasts (the cell type that makes up the placenta). Work over the past 10 years has shown a difference in gene expression in single-cells from placentas of pregnancies with preeclampsia compared to normotensive placentas. The next step in this field will be look at the specific genes that are different in the placenta cells and using that data to better understand how preeclampsia develops and also how it can be prevented and treated.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048492/
Citation: Naydenov DD, Vashukova ES, Barbitoff YA, Nasykhova YA, Glotov AS. Current Status and Prospects of the Single-Cell Sequencing Technologies for Revealing the Pathogenesis of Pregnancy-Associated Disorders. Genes (Basel). 2023 Mar 20;14(3):756. doi: 10.3390/genes14030756. PMID: 36981026; PMCID: PMC10048492.
About Research Roundup
Each quarter, our team of science writers reviews the most current research studies related to hypertensive disorders of pregnancy and summarizes those studies of greatest interest and potential impact to our community, including research studies related to risk assessment, diagnosis, prevention, and treatment. Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible, and to our Patient Advisory Council, who reviews these materials from the patient perspective.
Related Articles
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
1777566412.png)
Placental dysfunction can result in conditions such as preeclampsia, which have traditionally been managed with close monitoring and appropriately timed delivery. There is currently no cure for preecl...
1777563523.png)
Gestational hypertension continues to be a growing public health concern contributing to maternal morbidity, mortality, and long-term health complications in the U.S. While changes in vision—suc...
1777562643.png)
Background Low-dose aspirin (81 mg) is a treatment known to help lower the risk of preeclampsia. However, not everyone who is at higher risk is told to take it. This study looks at whether a screening...
Women who experienced Preeclampsia have a higher lifetime risk of developing cardiovascular disease (CVD) than women who did not suffer from this pregnancy complication. Researchers wanted to know if...
Recent findings in preeclampsia research have shown that preeclampsia likely has at least two variants – an early onset and a late onset variant. Early onset is typically defined as before 34 we...